Stockreport

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D [Yahoo! Finance]

Inventiva S.A. - American Depository Shares  (IVA) 
PDF Statistical significance was also achieved on several markers of liver injury, markers of glucose and lipid metabolism, as well as hepatic steatosis. Patients treated [Read more]